" class="no-js "lang="en-US"> Jennifer Perusini - Medtech Alert
Saturday, September 20, 2025
Jennifer Perusini

Jennifer Perusini

About Jennifer Perusini

Dr. Jennifer Perusini, a neuroscientist and entrepreneur, is the Founder and Chief Executive Officer of Neurovation Labs. Dr. Perusini’s doctoral work forms the basis of Neurovation Labs’ pioneering research, which made the groundbreaking discovery that there is a physiological component to Post-Traumatic Stress Disorder (PTSD) that can be targeted to both diagnose and treat the disorder. Dr. Perusini and her team have developed a patent pending detection method and are currently creating a companion treatment for PTSD.

Dr. Perusini earned her B.A. in Neuroscience & Behavior at Barnard College, Columbia University, and her Ph.D. in Behavioral Neuroscience at the University of California, Los Angeles, where she studied the mechanisms underlying PTSD in an animal model.  She completed her post-doctoral fellowship, which focused on rodent models of aging and Alzheimer’s disease, at Columbia University in the Departments of Psychiatry and Integrative Neuroscience.

Dr. Perusini is on the Board of Directors of both Women in Learning (WIL), a nationwide 501(c)(3) nonprofit organization dedicated to the support and advancement of women in science, and PTSD Recovery Foundation of America, a 501(c)(3) nonprofit organization that supports PTSD wellness and research. In 2020, Dr. Perusini received the Barnard College Young Alumna Award for her career in PTSD healthcare. She was recently named Chair of the Barnard Entrepreneurs Network (BEnet), an alumnae organization that supports entrepreneurs at all business stages across and within all industries, and serves on Barnard’s Leadership Council at Athena Center. In 2021, Dr. Perusini was elected to the Pavlovian Society Executive Committee. She is a presenter at national biotech industry events, has been featured in numerous publications, and frequently speaks on issues pertaining to women entrepreneurs across industries.

Related Story

Neurovation Labs Awarded Additional Air Force Phase II Contract Worth $1.25M to Develop Tools to Mitigate PTSD and Other Brain Traumas

June 22 2022

Neurovation Labs, Inc., a biotechnology company developing the first objective diagnostic and companion treatment for […]